ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2011
Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Identifying promising peptide targets for leprosy serological tests: From prediction to ELISA.Journal, genetic engineering & biotechnology · 2025Article
- HSP60 mimetic peptides from Mycobacterium leprae as new antigens for immunodiagnosis of Leprosy.AMB Express · 2023Article
- In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae.Immunological reviews · 2021Review
- Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach.In silico pharmacology · 2021Article
- Changes in B Cell Pool of Patients With Multibacillary Leprosy: Diminished Memory B Cell and Enhanced Mature B in Peripheral Blood.Frontiers in immunology · 2021Article
- Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2020Article
- Prospects for new leprosy diagnostic tools, a narrative review considering ELISA and PCR assays.Revista da Sociedade Brasileira de Medicina Tropical · 2020Review
- Biotechnological and Immunological Platforms Based on PGL-I Carbohydrate-Like Peptide ofFrontiers in microbiology · 2020Article
- A novel integrated molecular and serological analysis method to predict new cases of leprosy amongst household contacts.PLoS neglected tropical diseases · 2019Article
- Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil.BMC infectious diseases · 2019Article
- Accuracy of Enzyme-Linked Immunosorbent Assays (ELISAs) in Detecting Antibodies againstThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Review
- Article
- Specific antigen serologic tests in leprosy: implications for epidemiological surveillance of leprosy cases and household contacts.Memorias do Instituto Oswaldo Cruz · 2017Article
- Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases.PLoS neglected tropical diseases · 2017Article
- Identifying Leprosy and Those at Risk of Developing Leprosy by Detection of Antibodies against LID-1 and LID-NDO.PLoS neglected tropical diseases · 2016Article
- Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.Risk management and healthcare policy · 2016Review
- Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.Memorias do Instituto Oswaldo Cruz · 2015Article
- Antigen-specific assessment of the immunological status of various groups in a leprosy endemic region.BMC infectious diseases · 2015Article
- Leprosy in the 21st century.Clinical microbiology reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Although curable, leprosy requires better diagnostic and prognostic tools to accompany therapeutic strategies. We evaluated the serum samples of leprosy patients from Venezuela and Brazil for reactivity against the specific recombinant proteins, ML0405 and ML2331, and the LID-1 fusion protein that incorporates both of these antigens. Antigen-specific IgG was highest in lepromatous leprosy patients (LL) and decreased across the disease spectrum, such that only a small subset of true tuberculoid patients (TT) tested positive. The impact of multidrug therapy (MDT) on these antibody responses was also examined. Several years after treatment, the vast majority of Venezuelan patients did not possess circulating anti-LID-1, anti-ML0405, and anti-ML2331 IgG, and the seropositivity of the remaining cases could be attributed to irregular treatment. At discharge, the magnitude and proportion of positive responses of Brazilian patients against the proteins and phenolic glycolipid (PGL)-I were lower for most of the clinical forms. The monthly examination of IgG levels in LL patient sera after MDT initiation indicated that these responses are significantly reduced during treatment. Thus, responses against these antigens positively correlate with bacillary load, clinical forms, and operational classification at diagnosis. Our data indicate that these responses could be employed as an auxiliary tool for the assessment of treatment efficacy and disease relapse.
Indexed as
Identifiers
21544695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.